by | Apr 25, 2024 | Publications
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Apr;32(2):505-511. doi: 10.19746/j.cnki.issn.1009-2137.2024.02.028. ABSTRACT OBJECTIVE: To analyze the effect of recombinant human thrombopoietin (rhTPO) on platelet (PLT) reconstitution after autologous peripheral blood stem...
by | Apr 24, 2024 | Publications
Hematology. 2024 Dec;29(1):2343164. doi: 10.1080/16078454.2024.2343164. Epub 2024 Apr 23. ABSTRACT To evaluate whether patients with multiple myeloma (MM) could benefit from tandem autologous hematopoietic stem cell transplantation (auto-HSCT), PubMed, Embase, Web of...
by | Apr 24, 2024 | Publications
Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0210. Online ahead of print. ABSTRACT PURPOSE: Early intervention for High-Risk Smoldering Multiple Myeloma (HR-SMM) achieves deep and prolonged responses. It is unclear if beneficial outcomes are due to...
by | Apr 24, 2024 | Publications
Future Oncol. 2024 Apr 23. doi: 10.2217/fon-2023-0954. Online ahead of print. ABSTRACT WHAT IS THIS SUMMARY ABOUT?: This plain language summary describes the results of a Phase 3 study called KarMMa-3. In this ongoing study, researchers looked at a relatively new...
by | Apr 24, 2024 | Publications
Exp Hematol Oncol. 2024 Apr 23;13(1):45. doi: 10.1186/s40164-024-00507-5. ABSTRACT Histone deacetylase inhibitors (HDACis) are a significant category of pharmaceuticals that have developed in the past two decades to treat multiple myeloma. Four drugs in this category...
by | Apr 24, 2024 | Publications
Biomark Res. 2024 Apr 23;12(1):43. doi: 10.1186/s40364-024-00592-y. ABSTRACT BACKGROUND: Activation of CD28 on multiple myeloma (MM) plasma cells, by binding to CD80 and CD86 on dendritic cells, decreases proteasome subunit expression in the tumor cells and thereby...